Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
01:11pm, Thursday, 11'th Jul 2024
Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
12:31pm, Thursday, 11'th Jul 2024
Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.
US FDA declines to approve Novo Nordisk's weekly insulin
06:00pm, Wednesday, 10'th Jul 2024
The U.S. Food and Drug Administration has declined to approve Novo Nordisk's weekly insulin in patients with diabetes, the Danish drugmaker said on Wednesday.
Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec
05:45pm, Wednesday, 10'th Jul 2024
Bagsværd, Denmark, 10 July 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices
05:19pm, Wednesday, 10'th Jul 2024
Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk can be convinced to cut the U.S. prices of its popular Ozempic and Wegovy used for weight loss by publicly shaming the drugma
3 Pharma Stocks That Could Make Your Grandchildren Rich
02:34pm, Wednesday, 10'th Jul 2024
Pharmaceutical stocks have not set the world on fire, with a few exceptions. Since the pandemic ended, pharma stocks have largely fallen out of favor with investors amid declining sales and mixed fina
Weight Loss Drugs: Challenges with Affordability & Supply
02:11pm, Wednesday, 10'th Jul 2024
Affordability and supply are key challenges for GLP-1 weight loss drugs but these issues are actively being addressed, notes Maurits Pot. He and Rahul Jasuja assess the market opportunity of this part
Novo Nordisk, Indonesia's Bio Farma sign deal to produce insulin
03:33am, Wednesday, 10'th Jul 2024
Danish drugmaker Novo Nordisk has signed a deal with Indonesia's state-owned pharmaceutical company Bio Farma to produce insulin to combat diabetes in the Southeast Asian country, a Bio Farma senior o
Novo Nordisk shares take a hit after a report revealed Eli Lilly's better weight loss drug
06:21pm, Tuesday, 09'th Jul 2024
Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy, were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to fa
Novo Nordisk Falls as Study Says Eli Lilly Weight-Loss Ingredient More Effective
01:55pm, Tuesday, 09'th Jul 2024
The stock price of a pair of pharmaceutical companies are moving in opposite directions Tuesday following the publication of a new scientific study, with Eli Lilly (LLY) shares rising and American dep
Eli Lilly weight-loss drug found more effective than Novo Nordisk's Ozempic
11:26am, Tuesday, 09'th Jul 2024
Novo Nordisk (NYSE:NVO) shares fell and Eli Lilly and Co (NYSE:LLY) rose after a study found the US company's weight-loss drug may be more effective. Lilly's tirzepatide, branded as Mounjaro, was
Novo Nordisk's stock slumps after study finds Wegovy lags Lilly's Mounjaro in speed and scale of weight loss
07:34am, Tuesday, 09'th Jul 2024
The stock of Danish biotech Novo Nordisk was down 1.6% premarket Tuesday, after a study found that the company's obesity drug Wegovy lags its main rival, Eli Lilly & Co. Inc.'s Mounjaro, in speed and
Imperial College spin-out Myricx Bio lands £90m of new investment
07:32am, Tuesday, 09'th Jul 2024
An Imperial College spin-out has landed £90 million in Series-A funding backed by heavyweight investors, including an offshoot of the British Business Bank (BBB). Myricx Bio, the recipient of this fu
Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss
05:40am, Tuesday, 09'th Jul 2024
Shares in Novo Nordisk , maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to fa
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
07:44pm, Monday, 08'th Jul 2024
Patients lost more significantly more weight on Eli Lilly's Mounjaro than Novo Nordisk's Ozempic, according to a new study.
